CompletedPhase 4NCT03220737
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
Studying Cholera
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bavarian Nordic
- Principal Investigator
- Paul Andre de Lame, MDEmergent BioSolutions
- Intervention
- VAXCHORA (Cholera Vaccine, Live, Oral)(biological)
- Enrollment
- 550 enrolled
- Eligibility
- 2-17 years · All sexes
- Timeline
- 2017 – 2020
Study locations (10)
- Emory University, Atlanta, Georgia, United States
- Johnson County Clin-Trials, Inc., Lenexa, Kansas, United States
- Heartland Research Associates, LLC, Wichita, Kansas, United States
- University of Kentucky, Lexington, Kentucky, United States
- Boston Medical Center, Boston, Massachusetts, United States
- The Center for Pharmaceutical Research, Kansas City, Missouri, United States
- Rochester Clinical Research, Inc., Rochester, New York, United States
- Aventiv Research Inc., Columbus, Ohio, United States
- Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States
- Clinical Research Associates, Inc., Nashville, Tennessee, United States
Collaborators
Emergent BioSolutions
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03220737 on ClinicalTrials.govOther trials for Cholera
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07509047Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and ChildrenInternational Vaccine Institute
- RECRUITINGPHASE4NCT07487077Extended Dosing Intervals Trial for Oral Cholera Vaccine, KenyaAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT07304284Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-PlusInternational Vaccine Institute
- RECRUITINGNANCT06455852Vaccine- and Infection-derived Correlates of Protection for Cholera.Massachusetts General Hospital
- RECRUITINGNANCT06498817Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)Johns Hopkins Bloomberg School of Public Health
- RECRUITINGNANCT06003816Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)Johns Hopkins Bloomberg School of Public Health
- RECRUITINGNANCT05166850Preventative Intervention for Cholera for 7 DaysJohns Hopkins Bloomberg School of Public Health
- ACTIVE NOT RECRUITINGPHASE2NCT04326478Single Dose Azithromycin to Prevent Cholera in ChildrenMassachusetts General Hospital